Download full-text PDF

Source
http://dx.doi.org/10.1021/jm00289a005DOI Listing

Publication Analysis

Top Keywords

novel pharmacological
4
pharmacological activity
4
activity series
4
series substituted
4
substituted pyridines
4
novel
1
activity
1
series
1
substituted
1
pyridines
1

Similar Publications

Multi-ancestry genome-wide meta-analysis with 472,819 individuals identifies 32 novel risk loci for psoriasis.

J Transl Med

January 2025

Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.

Background: Psoriasis is a common chronic, recurrent, immune-mediated disease involved in the skin or joints or both. However, deeper insight into the genetic susceptibility of psoriasis is still unclear.

Methods: Here we performed the largest multi-ancestry meta-analysis of genome-wide association study including 28,869 psoriasis cases and 443,950 healthy controls.

View Article and Find Full Text PDF

C3AR1 as a target for preeclampsia: from bioinformatics and network pharmacology to experimental validation.

BMC Pregnancy Childbirth

January 2025

Obstetrics and Gynecology Center, Department of Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, China.

Background: Preeclampsia, characterized by hypertension and proteinuria during pregnancy, poses significant risks to both mother and fetus. The complement system's aberrant activation, notably the C3AR1, is important to the pathogenesis of preeclampsia, although the precise mechanisms are not fully understood.

Materials And Methods: Utilizing the Comparative Toxicogenomics Database (CTD) and Molecular Signatures Database (MSigDB), we identified complement system targets associated with preeclampsia and environmental pollutants.

View Article and Find Full Text PDF

Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib.

View Article and Find Full Text PDF

Variable power functional dilution adjustment of spot urine.

Sci Rep

January 2025

Praxis Dr.Carmine, Etzelstrasse 21, Pfaeffikon SZ, 8808, Switzerland.

Spot-urinary biomarkers are crucial in medical, epidemiological, and environmental studies, but their variability due to hydration levels requires precise dilution adjustments. Traditional methods, like conventional creatinine correction (CCRC), are limited in compensating for variations in urine concentration, causing substantial inconsistencies, particularly at the extremes of the diuresis spectrum. While restricting the creatinine (CRN) range to 0.

View Article and Find Full Text PDF

Advanced Peptide Nanozymes with Dual Antifungal Mechanisms: Cutting-Edge Innovations in Combatting Antimicrobial Resistance.

Curr Microbiol

January 2025

Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Poonamallee High Road, Chennai, Tamil Nadu, 600 077, India.

This letter commends the recent innovative research findings on "Dual-Action Antifungal Peptide Nanozymes: A Novel Approach to Combatting Antimicrobial Resistance." The study introduces a pioneering method to address antimicrobial resistance by developing peptide nanozymes that mimic antimicrobial peptides and enzymes through de novo design and peptide assembly. The heptapeptide IHIHICI, designed using AlphaFold2 and molecular dynamics simulations, exhibits high stability and dual antifungal actions, effectively killing over 90% of Candida albicans within 10 min.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!